Efficacy, Safety, and Tolerability Rollover Study of Eteplirsen in Subjects With Duchenne Muscular Dystrophy
Status:
Completed
Trial end date:
2017-08-16
Target enrollment:
Participant gender:
Summary
The primary objective of this study is to assess the ongoing efficacy, safety, and
tolerability of an additional 212 weeks of treatment with eteplirsen injection in Duchenne
muscular dystrophy (DMD) subjects who have successfully completed the 28 week eteplirsen
study: Study 4658-us-201. This study will also evaluate the correlation between biomarkers
for DMD and the clinical status of participating DMD subjects.